Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own0.50% Shs Outstand159.14M Perf Week-1.06%
Market Cap19.24B Forward P/E- EPS next Y-1.32 Insider Trans-28.86% Shs Float158.77M Perf Month-4.12%
Income-134.00M PEG- EPS next Q-0.53 Inst Own94.30% Short Float2.93% Perf Quarter23.66%
Sales751.00M P/S25.62 EPS this Y28.10% Inst Trans0.02% Short Ratio2.89 Perf Half Y79.60%
Book/sh10.31 P/B11.73 EPS next Y42.90% ROA-5.60% Target Price127.21 Perf Year97.02%
Cash/sh5.94 P/C20.36 EPS next 5Y25.00% ROE-9.00% 52W Range55.36 - 133.54 Perf YTD33.75%
Dividend- P/FCF- EPS past 5Y37.13% ROI-4.70% 52W High-9.46% Beta0.84
Dividend %- Quick Ratio5.20 Sales past 5Y18.30% Gross Margin82.70% 52W Low118.41% ATR4.40
Employees1681 Current Ratio6.00 Sales Q/Q57.20% Oper. Margin-19.70% RSI (14)52.83 Volatility2.46% 3.80%
OptionableYes Debt/Eq0.43 EPS Q/Q-9.30% Profit Margin-17.80% Rel Volume1.00 Prev Close121.65
ShortableYes LT Debt/Eq0.43 EarningsApr 30 AMC Payout- Avg Volume1.61M Price120.91
Recom1.80 SMA20-1.23% SMA506.41% SMA20039.57% Volume1,613,908 Change-0.61%
Mar-27-15Reiterated UBS Buy $112 → $136
Mar-27-15Reiterated Deutsche Bank Buy $90 → $140
Dec-19-14Reiterated RBC Capital Mkts Outperform $103 → $110
Dec-11-14Reiterated UBS Buy $87 → $112
Nov-25-14Reiterated RBC Capital Mkts Outperform $87 → $103
Oct-24-14Reiterated RBC Capital Mkts Outperform $77 → $87
Feb-19-14Reiterated Barclays Equal Weight $73 → $76
Jan-14-14Reiterated Deutsche Bank Buy $75 → $85
Jan-10-14Downgrade Barclays Overweight → Equal Weight $75 → $73
Oct-25-13Reiterated Barclays Overweight $70 → $75
Sep-18-13Downgrade Stifel Buy → Hold
Jul-26-13Reiterated Stifel Buy $67 → $70
Apr-03-13Reiterated Barclays Overweight $54 → $70
Mar-20-13Reiterated RBC Capital Mkts Outperform $58 → $64
Mar-20-13Reiterated Deutsche Bank Hold $45 → $59
Feb-22-13Reiterated RBC Capital Mkts Outperform $55 → $58
Feb-01-13Reiterated UBS Buy $53 → $67
Jan-22-13Upgrade Stifel Nicolaus Hold → Buy $67
Nov-06-12Reiterated Barclays Overweight $46 → $54
Nov-06-12Downgrade Brean Capital Buy → Hold
Apr-14-15 08:19AM  BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET at noodls
08:00AM  BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET GlobeNewswire
Apr-10-15 11:41AM  Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but Net Returns Were Only 5% Heres Why at Insider Monkey
10:00AM  The Oprahs Of Biotech: People Who Can Go By First Name Only at Forbes
Apr-09-15 09:30AM  Billionaire John Griffins Five Picks That Killed the Market This Quarter at Insider Monkey
Apr-06-15 05:20PM  Biotech Stocks Still Feeling Healthy Despite Bubble Talk at TheStreet
Apr-03-15 02:37PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits
Apr-02-15 12:33PM  Retrophin Hits High On Bullish Initiation Report at Investor's Business Daily
Apr-01-15 06:36PM  Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog
Mar-31-15 09:57PM  Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame at TheStreet
11:51AM  Biotech's next buzz: Gene therapy? at CNBC
07:53AM  How bubbles are blown: Biotech edition
Mar-30-15 06:58PM  Cramer tackles a tough tweet
09:26AM  BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting at noodls
09:00AM  BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting GlobeNewswire
08:51AM  BioMarin Pharmaceutical (BMRN) Shows Strength: Stock Up 11.5% - Tale of the Tape
Mar-27-15 06:40PM  BioMarin Pharma Hits All-Time High at Investor's Business Daily +11.45%
06:25PM  Four horsemen of semis & biotech: Cramer
05:54PM  BioMarin jumps after analyst suggests merger may be in its future at MarketWatch
04:46PM  Shire shines on fourth day of FTSE falls at Financial Times
04:28PM  Equities snapped its four day losing streak...
04:11PM  Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks Amici Capital Is Bullish on at Insider Monkey
03:44PM  BioMarin Pharmaceutical (BMRN) Stock Gains Today on Merger Rumors at TheStreet
02:30PM  Street Talk: Zayo Group under the radar
08:35AM  RBC Has 4 Biotech Stocks to Buy After Massive Pullback at 24/7 Wall St.
Mar-26-15 12:12PM  Biotech Stock Selloff: Is It Justified? at Investor's Business Daily
09:47AM  The Biotech Selloff: It's Déjà Vu All Over Again at Barrons.com
Mar-25-15 10:03AM  Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)s 18% Spike at Insider Monkey -6.00%
Mar-24-15 06:28AM  Profit takers active as biotech stalls
Mar-23-15 08:50AM  Cramer's stocks to watch: Amazing biotech
08:33AM  Biotech's path to discovery: BioMarin CEO
Mar-18-15 04:30PM  Biotech Bull Market: The Two Best Ways to Play It at Barrons.com
02:10PM  How the Weaker Euro Is Impacting Biotech Earnings at 24/7 Wall St.
08:00AM  BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-16-15 06:17PM  Cramer: This sector has tons of hidden opportunity at CNBC
08:51AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Moves Up 6.9% - Tale of the Tape
Mar-13-15 12:17PM  Short Sellers Still Attracted To Biotech Stocks +6.86%
Mar-12-15 08:07PM  Lightning Round: Good chance this is downgraded at CNBC
Mar-11-15 12:04PM  18 Biotech Stocks These Wall Street Analysts Are Tracking
Mar-10-15 03:17PM  United Therapeutics Wins FDA Nod, Priority Voucher at Investor's Business Daily
Mar-06-15 03:24PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers
08:20AM  The Next 3 Likely Biotech Buyout Candidates at 24/7 Wall St.
Mar-05-15 07:08PM  10-K for BioMarin Pharmaceutical, Inc. at Company Spotlight
06:13PM  Cramer: This X factor is ignored in your portfolio at CNBC
04:02PM  Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst
Mar-03-15 10:09AM  BioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management at Insider Monkey
Feb-27-15 10:10AM  Company News for February 27, 2015 - Corporate Summary
09:30AM  Cowen Raises Price Targets on Top Momentum Stocks at 24/7 Wall St.
Feb-26-15 11:50AM  Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog Zacks
11:20AM  Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks
10:20AM  Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Zacks
09:56AM  Merge Healthcare (MRGE) Q4 Earnings Up Y/Y; Revenues Miss - Analyst Blog Zacks
09:50AM  BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Zacks
09:30AM  Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Zacks
Feb-25-15 07:29PM  Lightning Round: This group goes higher tomorrow at CNBC
04:46PM  BioMarin reports 4Q loss AP
04:30PM  Biomarin Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:20PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results GlobeNewswire
11:47AM  PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer at TheStreet
09:32AM  Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Zacks
07:07AM  Q4 2014 Biomarin Pharmaceutical Inc Earnings Release - After Market Close CCBN
Feb-24-15 06:51PM  Illumina Expands NGS Portfolio with NeoPrep Library System - Analyst Blog Zacks
06:24PM  Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Zacks
Feb-23-15 07:02PM  Cramer Remix: Where's the Nasdaq bubble? at CNBC
06:50PM  Lightning Round: Don't listen to this CEO at CNBC
06:20PM  Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog Zacks
04:20PM  Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog Zacks
Feb-20-15 04:15PM  BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
02:30PM  Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog Zacks
Feb-19-15 06:24PM  Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog Zacks
05:10PM  Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog Zacks
12:20PM  Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog Zacks
Feb-18-15 05:50PM  Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog Zacks
04:08PM  Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog Zacks
Feb-17-15 09:20AM  Actelion's (ALIOF) Earnings & Revenues Fall Y/Y in Q4 - Analyst Blog Zacks
09:11AM  Synthetic Biologics (SYN) Jumps: Stock Up 9.2% - Tale of the Tape Zacks
Feb-16-15 04:40PM  AstraZeneca's Patent for Pulmicort Respules Found Invalid - Analyst Blog Zacks
04:10PM  Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog Zacks
Feb-13-15 09:26AM  Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog Zacks
Feb-12-15 04:10PM  Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog Zacks
12:40PM  Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog Zacks
Feb-11-15 02:42PM  Isis Pharma to Get $5M from Biogen - Analyst Blog Zacks
01:30PM  Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog Zacks
10:06AM  Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog Zacks
09:18AM  Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog Zacks
Feb-10-15 04:38PM  Regeneron Earnings Growth Falls Short, But Eylea Sales, '15 Outlook Are Solid Investor's Business Daily
12:16PM  Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution GlobeNewswire
11:01AM  Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea at Investor's Business Daily
Feb-09-15 02:43PM  Analyst Sees BioMarin Up Another 25% at 24/7 Wall St.
08:00AM  BioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM) GlobeNewswire
Feb-04-15 08:00AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
Feb-03-15 08:00AM  BioMarin to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Wednesday, February 25 at 4:30pm ET GlobeNewswire
Jan-30-15 08:13AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Stateme EDGAR Online
08:00AM  BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period GlobeNewswire
Jan-29-15 02:27PM  When does the biotech party end? at CNBC
Jan-28-15 06:25PM  Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog Zacks
Jan-27-15 07:30AM  Rare feat: BioMarin rewrites playbook for small-market drug approvals at American City Business Journals
06:00AM  Jim Cramer's Top Stock Picks: BMRN HSY KMB at TheStreet
Jan-26-15 08:22PM  Jim Cramer's 'Mad Money' Recap: 8 Ways to Tell a Healthy Market From a Sick One at TheStreet
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Option Exercise6.4622,546145,64755,804Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.5322,5462,717,54633,258Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.533,506422,590251,251Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 20Sale126.401,000126,39633,258Mar 24 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 17Sale124.871,000124,86634,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Option Exercise21.5140,000860,400129,950Mar 18 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale123.481,000123,47735,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Sale123.5741,3155,105,16688,635Mar 18 07:50 PM
Davis George EricSVP, General CounselMar 13Option Exercise37.0815,000556,23988,846Mar 17 06:03 PM
Davis George EricSVP, General CounselMar 13Sale120.8715,0001,813,00273,846Mar 17 06:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale114.892,021232,20136,258Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise12.9915,000194,85057,279Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale112.1319,0002,130,38338,279Mar 11 06:32 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Option Exercise17.1114,051240,364123,751Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Option Exercise12.9910,000129,90052,279Mar 05 08:20 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Sale116.3714,0511,635,091109,700Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Sale113.7010,0001,137,01642,279Mar 05 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Option Exercise9.865004,93043,695Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Sale107.7191698,66042,279Mar 04 07:39 PM
LAPALME PIERREDirectorMar 03Option Exercise14.2420,000284,80050,150Mar 05 05:34 PM
Mueller BrianVP, Corporate ControllerMar 03Option Exercise28.237,000197,61015,800Mar 05 05:31 PM
Mueller BrianVP, Corporate ControllerMar 03Sale109.467,000766,2108,800Mar 05 05:31 PM
LAPALME PIERREDirectorMar 03Sale106.5720,0002,131,40030,150Mar 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 03Sale107.425,000537,097215,157Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise12.993,00038,97046,195Mar 04 07:39 PM
Davis George EricSVP, General CounselMar 02Option Exercise26.4923,000609,27087,246Mar 04 07:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Option Exercise39.0615,500605,43084,176Mar 04 07:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale107.0015,5001,658,50068,676Mar 04 07:48 PM
Davis George EricSVP, General CounselMar 02Sale108.3123,0002,491,02764,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale107.963,000323,89343,195Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale108.445,000542,195220,157Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale94.142,000188,286225,157Jan 13 07:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Option Exercise12.993,00038,97046,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.733,000266,19343,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.732,000177,462227,157Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Option Exercise12.992,00025,98045,195Dec 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Sale95.002,000190,00043,195Dec 12 01:51 PM
LEWIS ALANDirectorDec 04Option Exercise21.517,500161,32528,900Dec 08 06:50 PM
LEWIS ALANDirectorDec 04Sale89.907,500674,22521,400Dec 08 06:50 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Option Exercise38.5912,000463,08043,590Dec 05 05:26 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Sale91.0112,0001,092,16131,590Dec 05 05:26 PM
Mueller BrianVP, Corporate ControllerDec 02Option Exercise28.235,000141,1509,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 02Sale91.825,000459,1004,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Option Exercise20.986,950145,78511,543Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Sale90.256,950627,2384,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerNov 26Sale88.973,400302,5084,593Dec 02 05:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Option Exercise12.992,00025,98045,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Option Exercise26.4920,000529,80084,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Sale90.002,000180,00043,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Sale89.7520,0001,795,00064,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 12Sale81.511,00081,513228,157Nov 14 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Option Exercise12.994,00051,96047,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Option Exercise21.5120,000430,20096,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Sale87.004,000348,00043,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Sale86.5520,0001,730,98276,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 03Sale85.333,000256,00243,195Nov 05 07:45 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 03Sale83.54473,92631,590Nov 05 07:44 PM
BAFFI ROBERTEVP, Technical OperationsOct 30Option Exercise38.5929,9631,156,272129,163Oct 31 02:58 PM
Davis George EricSVP, General CounselOct 30Option Exercise26.4915,000397,35079,426Nov 03 07:21 PM
Davis George EricSVP, General CounselOct 30Sale83.2015,0001,247,93064,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 29Option Exercise33.7445,4621,533,721144,662Oct 31 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise12.992,00025,98048,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Sale80.002,000160,00046,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Option Exercise12.992,00025,98048,195Oct 23 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Sale75.002,000150,00046,195Oct 23 06:34 PM
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 03Sale69.77181,25668,733Feb 10 12:57 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 22Sale56.881,00056,87646,195May 23 12:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale56.191,54586,81747,195May 22 06:27 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 16Sale56.861,864105,99460,950May 19 06:28 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 16Sale56.911,00457,13620,980May 19 06:27 PM
LAWLIS V BRYANDirectorMay 16Sale56.871,70096,6729,700May 19 06:31 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale58.231,43483,49864,850May 14 07:58 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale58.1847827,80923,080May 14 07:20 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 09Sale57.913,479201,47467,850May 12 04:46 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale57.9662135,99224,080May 13 04:44 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 02Sale58.571164468,737Feb 10 12:57 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 01Sale59.6771542,66673,850May 05 08:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 01Sale59.5566639,66125,380May 05 04:00 PM